Who mentions $RGNX most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $RGNX most — 16 mentions in the past 12 months.

When was $RGNX first mentioned on Surfaced?

The earliest tracked mention of $RGNX in the Surfaced archive was on Oct 8, 2025.

How many voices track $RGNX?

2 FinTwit voices have mentioned $RGNX 17 times in the past 12 months.

What kind of voices mention $RGNX most?

$RGNX is mentioned most by Biotech voices on Surfaced.

$RGNX — FinTwit mentions on Surfaced

Recent mentions

17 mentions

@adamfeuersteinJun 24, 2026 · 12:14 PM

Wagering on FDA changes, Regenxbio $RGNX will submit Duchenne gene therapy for approval https://t.co/VeVHWXu903 via @Jasonmmast

Open on X

@adamfeuersteinJun 22, 2026 · 10:44 AM

FDA reverses course on Regenxbio’s $RGNX childhood gene therapy after rejection https://t.co/VoNaSAZ4wm via @Jasonmmast

Open on X

@investmentguru_Jun 21, 2026 · 2:24 PM

The Next Trillion-Dollar Wave Isn’t in Semiconductors. It’s in Your Bloodstream. Everyone’s watching chips, NeoCloud, and power. Meanwhile, AI is quietly rewiring healthcare from reactive to predictive — and almost nobody is positioned for it. Healthcare is moving through the same kind of capital cycle we’ve mapped in AI infrastructure: a foundational layer (genomics) enabling a diagnostic layer (AI-read data) enabling a delivery layer (personalized treatment) enabling a behavioral layer (digital therapeutics that keep patients engaged). Four layers, four sets of plays. 1. Gene Therapies — The Foundational Layer This is the “silicon” of biotech: rewrite the underlying code, fix the disease at the source. 2026 has been a genuine inflection point — the FDA has leaned into faster, more flexible review pathways for cell and gene therapies, and the pipeline is converting. •$QURE (uniQure) — surged sharply this month on a major gene therapy advancement; a name riding the regulatory tailwind directly •$RGNX (REGENXBIO) — AAV gene therapy platform with a PDUFA decision already through in February and multiple late-stage pivotal readouts through 2026; partnered with AbbVie on what could be the first gene therapy for a non-rare disease (wet AMD) •$NTLA (Intellia) / $CRSP (CRISPR Therapeutics) / $BEAM (Beam Therapeutics) — the core gene-editing complex; CRSP remains range-bound despite holding the world’s first approved CRISPR therapy, which is exactly the kind of “stuck but structurally important” setup worth tracking 2. AI-Assisted Diagnostics — The Inference Layer This is where AI infrastructure spend actually shows up as patient outcomes. The model: ingest multimodal data (genomic, imaging, clinical), run inference, return an actionable diagnosis faster than a human panel. •$TEM (Tempus AI) — the clearest pure-play. Q1 2026 revenue +36% YoY to $348M, diagnostics revenue +35%, MRD test volume up ~500% YoY, full-year guidance raised to $1.59–1.60B. This is the diagnostics version of a NeoCloud growth curve •$PACB (Pacific Biosciences) — sequencing infrastructure, the “memory layer” underneath every genomic diagnostic •$BFLY (Butterfly Network) — point-of-care imaging, AI-assisted ultrasound, democratizing diagnostic access 3. Precision Medicine — The Targeting Layer Where genomics and diagnostics converge into “right drug, right patient, right time.” •$PRAX (Praxis Precision Medicines) — CNS precision neuroscience, translating genetic epilepsy insights into targeted therapies, multiple readouts ahead in 2026 •$RGNX again earns a mention here — its retinal and Duchenne programs are precision-targeted by genetic subtype, not blanket indications •Watch the AbbVie/Gilead-style partnership pattern — Big Pharma is increasingly outsourcing precision targeting to smaller platform companies rather than building in-house, which is where the asymmetric upside sits 4. Digital Therapeutics — The Engagement Layer The layer that keeps patients adherent and reduces cost-of-care between clinical touchpoints — software as the prescription. •$HIMS (Hims & Hers) — already a long-term holding in the core portfolio; consumer-facing digital health at scale •$GDRX (GoodRx) — Pharma Direct revenue +82% YoY in Q1 2026, a real signal that the direct-to-consumer medication/therapeutics rail is accelerating •$TDOC (Teladoc) — legacy name still worth tracking as the digital-care distribution layer consolidates The framework, simply: Genomics writes the code → AI reads the code → precision medicine targets the code → digital therapeutics keeps you compliant with the fix. Same wave structure as chips → memory → photonics → energy, just running through biology instead of silicon. This sector moves on binary catalysts (PDUFA dates, trial readouts) rather than smooth growth curves like NeoCloud — size positions accordingly and expect volatility around data releases. Not financial advice.

Open on X

@adamfeuersteinMay 14, 2026 · 12:48 PM

@pemulisking Approval standard is the biggest overhang, I think. $RGNX single-arm study using correlative analysis to link microD expression to muscle benefit vs $SLDB going with a placebo controlled study to do the same.

Open on X

@adamfeuersteinMay 14, 2026 · 11:07 AM

$RGNX Duchenne gene therapy study results are out: microdystrophin expression reached an average of 71% of normal across all 31 boys at 12 wks. Functional improvements in a subset of boys followed for one year also seen. The big question remains: Will the FDA still follow the $SRPT precedent and grant accelerated approval to the Regenxbio gene therapy? CEO Curran Simpson told me the company is holding off on submitting to the FDA until early next year. “I think our data checks every single box that you would want for accelerated approval,” he told me. "We’re not in a rush to go to the FDA at this point. We want to give time for the leadership changes to occur. But that’s OK, because we can still meet our timeline of securing an approval in 2027." More details in our story, written with @Jasonmmast in the following post.

Open on X

@adamfeuersteinMay 14, 2026 · 11:07 AM

Here's our $RGNX story https://t.co/1sxVUSDZCB

Open on X

@adamfeuersteinMar 19, 2026 · 7:20 PM

This week's Biotech Scorecard newsletter: Six drugmakers, six months: Charting the FDA’s course in the post-Prasad era $REPL Pierre Fabre $ATRA $QURE $CAPR $RGNX https://t.co/sGa7G6YTDn

Open on X

@adamfeuersteinFeb 26, 2026 · 4:34 PM

(Hopefully) Final word today on the Makary $QURE (or was it $RGNX) thing: Bottom line: Makary shouldn't be talking publicly about unresolved drug applications. Uniqure doesn't even have an application submitted; and RegenxBio's CRL letter isn't posted to the FDA's web site. Also, does Makary even know what the hell he's talking about? "...there was a product where the researchers drilled a burr hole, literally a hole in people's skulls..." That's Uniqure, clearly. But... "...inject intrathecally into the ventricle..." could be RegenxBio, which is injected into the spine. Is Makary conflating two different therapies? Total shitshow...

Open on X

@adamfeuersteinFeb 26, 2026 · 2:46 PM

@BiotechAnalysst $RGNX therapy is delivered intrathecally into the spine, not via a burr hole in the head like $QURE

Open on X

@adamfeuersteinFeb 18, 2026 · 5:07 PM

"Prasad" stocks today: $CAPR +11%, $REPL +11%, $QURE +9%. $RGNX $SLDB up, too

Open on X

@adamfeuersteinFeb 12, 2026 · 3:08 PM

This week's Biotech Scorecard newsletter: The old Vinay Prasad never left. He just changed jobs Submissions to the FDA are handled by teams of reviewers, of course. But when I look across all of these recent cases, I see a consistent throwback to the old Prasad — questioning the legitimacy of biomarkers, surrogate endpoints, and single-arm clinical trials, even in the setting of rare diseases. In some of these rare-disease drug rejections, Atara $ATRA and Regenxbio $RGNX are good examples, Prasad or the staffers he directs aren’t following the agency’s own guidance. Companies are told early that their clinical development programs meet FDA requirements, but then, almost arbitrarily, the FDA changes the rules. Uniqure $QURE and its gene therapy for Huntington’s disease have been in a holding pattern for months because guidance it received long ago from the FDA is now, under Prasad’s watch, null and void. Read more at link below...

Open on X

@adamfeuersteinFeb 9, 2026 · 9:26 PM

FDA rejects Regenxbio’s $RGNX rare-disease gene therapy Agency raised questions about the surrogate biomarker used to predict clinical benefit in Hunter syndrome https://t.co/LZSIHMMe73

Open on X

@adamfeuersteinFeb 9, 2026 · 9:12 PM

$RGNX Hunter syndrome gene therapy rejected by FDA

Open on X

@adamfeuersteinJan 28, 2026 · 12:45 PM

$RGNX A question that is likely to come up today -- How different or similar are the MPS gene therapies to RGX-202, its gene therapy for DMD? I asked the company: "RGX-202 which is in pivotal study for Duchenne is a completely different therapy than either RGX-121 or RGX-111. RGX-202 uses systemic delivery of a novel construct that includes the AAV8 vector, a microdystrophin with the CT domain, and different promoter. We have seen no SAEs or AESIs in the Phase I/II trial of RGX-202. RGX-121 and RGX-111 use AAV9."

Open on X

@adamfeuersteinJan 28, 2026 · 12:33 PM

BREAKING: FDA halts $RGNX gene therapy trials after brain tumor found in patient. Tumor found in patient treated with MPS I therapy. FDA placed hold on it and the MPS II therapy. They are similar constructs. The MPS II therapy has a Feb. 8 PDUFA date, now up in the air. https://t.co/oU23gsA5G2 via @Jasonmmast

Open on X

@adamfeuersteinJan 12, 2026 · 5:07 PM

$SRPT Elevidys Q4 sales $110M vs consensus $120M At his #JPM26 presentation, CEO Doug Ingram notes 80% of addressable ambulatory DMD patients remain untreated. He sees this a huge opportunity for Elevidys, but I will note it's also the same for $SLDB and $RGNX and others developing next-gen gene therapies.

Open on X

@adamfeuersteinOct 8, 2025 · 4:06 PM

Duchenne gene therapy stocks today: $SLDB +22% $RGNX +14% $SRPT +1%

Open on X

$RGNX

$RGNX

About this stock

Related stocks

Frequently asked